C12N2770/24111 - CPC Classification Index

ClassID:

111312 ⎘

C12N2770/24111 - CPC Classification

Classification description:

ssRNA viruses positive-sense; Details; Flaviviridae Flavivirus, e.g. yellow fever virus, dengue, JEV

Sub-classes:

C12N2770/24121 » Viruses as such, e.g. new isolates, mutants or their genomic sequences 76
C12N2770/24122 » New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes 403
C12N2770/24123 » Virus like particles [VLP] 62
C12N2770/24131 » Uses of virus other than therapeutic or vaccine, e.g. disinfectant 5
C12N2770/24132 » Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent 25
C12N2770/24133 » Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory 6
C12N2770/24134 » Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein 527
C12N2770/24141 » Use of virus, viral particle or viral elements as a vector 11
C12N2770/24151 » Methods of production or purification of viral material 107
C12N2770/24161 » Methods of inactivation or attenuation 48
C12N2770/24171 » Demonstrated in vivo effect 99
C12N2770/24188 » For redistribution 0

Recent Application in this class:

20240158475

2024-05-16

NS1-BINDING PROTEIN

20230102223

2023-03-30

PHARMACEUTICAL COMPOSITIONS WITH ANTIFLAVIVIRAL ACTIVITY

20230040417

2023-02-09

DEFECTIVE INTERFERING PARTICLES

20200368344

2020-11-26

CHIKV RNA vaccines

20200101150

2020-04-02

Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes

20190315838

2019-10-17

Antibodies that bind zika virus envelope protein and uses thereof

20190160028

2019-05-30

Pharmaceutical compositions with antiflaviviral activity

20190085058

2019-03-21

DNA antibody constructs and method of using same

20190060438

2019-02-28

Infectious disease vaccines

#10

20180000925

2018-01-04

Viral RNA segments as immunomodulatory agents and vaccine components

#11

20170196963

2017-07-13

Drug target and construct for Japanese encephalitis virus infection

#12

20160311891

2016-10-27

DNA antibody constructs and method of using same

#13

20140248336

2014-09-04

siRNA useful in the treatment of flavivirus infection

#14

20130336929

2013-12-19

Methods and cells for identifying RIG-I pathway regulators

#15

20130067609

2013-03-14

Mammalian Genes Involved in Tularemia and Other Infections

#16

20120201782

2012-08-09

Peptide, adjuvants, vaccines, and methods of use

#17

20120065373

2012-03-15

DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND NUCLEOTIDE SEQUENCE

#18

20100190147

2010-07-29

Method of determining immune enhancement of virus infectivity using Fc receptor-transfected cell lines

#19

20100166704

2010-07-01

Methods and compositions for inhibition of viral replication

#20

20100041015

2010-02-18

COMPETITIVE ENZYME LINKED IMMUNOSORBENT ASSAY (C-ELISA) FOR THE DETECTION OF A FLAVIVIRUS SPECIFIC ANTIBODY

#21

20090304735

2009-12-10

Immunogenic Compositions

#22

20090186842

2009-07-23

Methods and compositions for inhibition of viral replication

#23

20090181036

2009-07-16

Pharmaceutical Compositions and Articles of Manufacture Useful in Reversal of a Clinical Episode of an Incurable Disease and Methods of Use Thereof

#24

20090047338

2009-02-19

Method to Treat Flavivirus Infection with siRNA

#25

20090010907

2009-01-08

Dnazymes for Inhibition of Japanese Encephalitis Virus Replication

#26

20070122801

2007-05-31

Binding molecules capable of neutralizing West Nile virus and uses thereof

#27

20070042359

2007-02-22

Binding molecules capable of neutralizing west nile virus and uses thereof